July 29, 2014 3:26 PM ET


Company Overview of Ceregene, Inc.

Company Overview

Ceregene, Inc. develops treatment of neurodegenerative disorders using the delivery of nervous system growth factors. Its therapeutic programs include CERE-110, an AAV vector delivery system that is in a Phase II clinical trial for the treatment of Alzheimer’s disease. The company was incorporated in 2000 and is based in San Diego, California. As of October 1, 2013, Ceregene, Inc. operates as a subsidiary of Sangamo Biosciences Inc.

9381 Judicial Drive

Suite 130

San Diego, CA 92121

United States

Founded in 2000





Key Executives for Ceregene, Inc.

Chief Executive Officer
Co-Founder and Chairman
Age: 65
Chief Scientific Officer and Executive Vice President
Age: 67
Senior Director of Human Resources and Administration
Compensation as of Fiscal Year 2014.

Ceregene, Inc. Key Developments

Ceregene, Inc. Auditor Raises 'Going Concern' Doubt

Ceregene, Inc. filed its 8-K/A on Dec 09, 2013 for the period ending Dec 31, 2012. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Ceregene, Inc., Sangamo Biosciences Inc. - M&A Call

To discuss the acquisition and provide a general business overview

Ceregene, Inc. Reports Data from Parkinson's Disease Phase 2b Study

Ceregene, Inc. announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120, a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. The trial did not demonstrate statistically significant efficacy on the primary endpoint. However, one of the key secondary endpoints, as defined and prespecified in the Statistical Analysis Plan, did produce statistically significant benefit. The trial also provided further evidence for the safety of CERE-120 and the dosing methods employed. A marked placebo effect was observed in this trial in that both the sham-surgery-control patients and the CERE-120 treated patients showed significant improvement following their surgery. Fifty-one patients with moderately advanced Parkinson's disease who could not be satisfactorily controlled with conventional Parkinson's medication were enrolled in the study at 11 leading clinical sites throughout the U.S. Approximately half of the patients received CERE-120 while the other half received sham (placebo) surgery as a control. Patients were monitored for 15-24 months to assess safety and changes in Parkinson's disease symptoms, using multiple endpoints such as the Unified Parkinson's Disease Rating Scale, Daily Diaries that assess motor function throughout the day, and PDQ-39, among others. Ceregene continues to analyze the data from this trial to gain as much information as possible.

Similar Private Companies By Industry

Company Name Region
Carigent Therapeutics, Inc. United States
DryLet, LLC United States
Ekteino Laboratories, Inc. United States
GenoRx, Inc. United States
Ultra Voice United States

Recent Private Companies Transactions

August 26, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ceregene, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.